Immatics N.V. IMTX
Set alert
7.20 USD -0.11 -1.50%
At close
7.01 -0.19 -2.64%
Pre-market · Nov 2, 4:59 AM ET
6.81 Day range 7.40
6.65 52-week range 12.41
- YTD
- -31.43%
- 1 year
- -29.34%
- Open
- 7.26
- Prev close
- 7.31
- Mkt cap
- 1.10B
- Vol
- 1.72M
- Avg vol
- 810.06K
- EPS
- -1.87
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 6.81
- High
- 7.40
- Forward P/E
- -3.57
- Beta
- 1.36
- Short ratio
- 4.03
- Inst. own
- 66.81%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 17, 2026
- 50-d avg
- 8.28
- 200-d avg
- 9.60
- 1y target
- 16.97
News
-
1 week ago benzinga.com
Reported Saturday, Immatics Reports IMA203CD8 Cell Therapy 51% ORR, 41% cORR Across Multiple Solid Tumors With Manageable Safety; IMA402 Bispecific Shows 32% cORR In PRAME-High Melanoma, Favorable Safety Profile
IMA402 PRAME bispecific continues to demonstrate encouraging anti-tumor activity in multiple indications, alongside a favorable safety profileIMA402 achieved a cORR of 32%, 12.5 months median DOR and…
2 weeks ago benzinga.com
This Entegris Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Analysts initiated coverage on VYLR, IMTX, ENTG, SLGL and SPTX, assigning Neutral, Buy or Overweight ratings and price targets.
-
2 weeks ago benzinga.com
Stifel Initiates Coverage On Immatics with Buy Rating, Announces Price Target of $15
Stifel analyst Laura Prendergast initiates coverage on Immatics (NASDAQ:IMTX) with a Buy rating and announces Price Target of $15.